Strides Bengaluru unit gets 'Voluntary Indicated Action' status from USFDA
The flagship facility in Bengaluru is the largest manufacturing facility for the company with capabilities to produce finished dosage products across multiple formats
 "Strides Bengaluru unit gets 'Voluntary Indicated Action' status from USFDA")
premium
Strides Pharma Science Limited today announced that its formulation facility in Bengaluru went through a United States food and drug adiministration (USFDA) inspection that ended on May 24th, 2019.
The inspection was completed successfully with a Voluntary Action Indicated (VAI) classification, said the company.
As per USFDA, VAI means that though "objectionable practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action”.
As per USFDA, VAI means that though "objectionable practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action”.
The flagship facility in Bengaluru is the largest manufacturing facility for the company with capabilities to produce finished dosage products across multiple formats including capsules, ointments, creams and liquids.
The Banglore facility services the key regulated markets of the US, Europe, and Australia.
As per the USFDA, VAI means that though “objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action”.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%